Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

RedX Pharma plc (REDX) Ordinary Shares 1p

Sell:7.00p Buy:8.00p 0 Change: No change
Market closed Prices as at close on 18 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.00p
Buy:8.00p
Change: No change
Market closed Prices as at close on 18 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.00p
Buy:8.00p
Change: No change
Market closed Prices as at close on 18 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohn’s disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.

Contact details

Address:
Block 33, Mereside,, Alderley Park
MACCLESFIELD
SK10 4TG
United Kingdom
Telephone:
+44 (0151) 7064747
Website:
https://redxpharma.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 10 June 2019 10/06/19
AGM 23 January 2019 23/01/19
Annual report 28 December 2018 28/12/18

General stock information

EPIC:
REDX
ISIN:
GB00BSNB6S51
Market cap:
£9.49 million
Shares in issue:
126.48 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Lisa Anson
    Chief Executive Officer, Director
  • Neil Murray
    Founder, Executive Director
  • Peter Jackson
    Co-Founder, Non-Executive Director
  • James Mead
    Chief Financial Officer, Executive Director
  • Derek Lindsay
    Chief Operating Officer
  • Simon Thorn
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.